SOURCE: Tufts Center for the Study of Drug Development

Tufts Center for the Study of Drug Development

January 20, 2010 09:00 ET

U.S. Orphan Product Designations More Than Doubled During Last Decade, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - January 20, 2010) - The number of orphan product designations in the U.S. more than doubled during the last decade, reflecting growing interest by pharmaceutical and biotech companies in developing products to treat orphan diseases, according to a study recently completed by the Tufts Center for the Study of Drug Development.

According to Tufts CSDD, orphan product designations increased from 208 in the 2000-02 period to 425 in 2006-08.

Orphan drugs are products developed for a rare disease or condition, which affects fewer than 200,000 people in the U.S. In the European Union, orphan products are defined as those for diseases or conditions affecting five people out of every 10,000, or fewer.

"The Orphan Drug Act, without question, can be considered a success. It has been emulated throughout the world, and today Japan and Europe have similar programs, while Singapore and Australia give special allowance for the importation and marketing approval of orphan products approved in the U.S.," said Tufts CSDD Associate Director Christopher-Paul Milne, who conducted the study.

Since the Orphan Drug Act of 1983 was signed into law in the U.S. more than 2,000 products in development have been designated as orphan drugs, while the Food and Drug Administration has granted market approval to 350 drugs and biologicals.

The new analysis, reported in the January/February Tufts CSDD Impact Report, released today, also found that:

    -- During the 2000s, orphan products comprised 22% of all new molecular
       entities (NMEs) and 31% of all significant biologics (SBs) receiving
       U.S. marketing approval.

    -- Orphan products receiving priority review status rose from 35% of
       all orphan NMEs in 2000-02 to 50% in 2006-08; during the same time
       the share of orphan SBs receiving priority review status rose from
       17% to 67%.

    -- While biotech firms during the 2000s garnered, on average, about
       one-third of all orphan drug approvals, they received just over 50%
       of orphan drug designations.

    -- Sponsors engaged in clinical development funded through orphan
       grants reported that 22% of their programs led to approvals, which
       compares with a clinical approval success rate of 16% among
       mainstream drug developers.

About the Tufts Center for the Study of Drug Development

The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes the Tufts CSDD Impact Report, a bi-monthly newsletter providing analysis and insight into critical drug development issues.

Contact Information

  • Contact:
    Tufts Center for the Study of Drug Development
    Peg Hewitt
    617-636-2185
    Email Contact

    Business Communication Strategies
    Peter Lowy
    617-734-9980
    Email Contact